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Increasing use of generic drugs is essential to maintain comprehensive and equitable 
healthcare, given current pressure on budgets through, for instance, ageing populations. 
Initiatives among health authorities to promote generic prescribing include educational 
initiatives (which in the United Kingdom has resulted in high levels of prescribing of 
international non-proprietary name (INN) drugs in over 80% of all prescriptions), compulsory 
JHQHULFVXEVWLWXWLRQLQSKDUPDFLHVDQGSDWLHQWVSD\LQJH[WUD³RXWRISRFNHW´expenses for a 
proprietary drug.[1-3] Concerns remain, however, about generic prescribing or compulsory 
substitution in certain drugs and drug classes, including lithium, theophyllines, some anti-
epileptic drugs, and the immunosuppressants evaluated in the linked study by Molnar and 
colleagues (doi:10.1136/bmj.h3163).[1] [4] 
Strict regulations govern market authorisation for generic drugs [5]. Regulators such as the 
European Medicines Agency (EMA) and the United States Food and Drug Administration 
(FDA) require manufacturers to show bioequivalence between a generic and a proprietary 
version of the same drug [6]. Subsequent meta-analyses have found no difference in 
outcomes between generics and originators across several classes of drugs, including 
cardiovascular medicines.[7] 
Strict regulation helps to limit concerns about INN prescribing or generic substitution. 
Several studies have reported that proprietary drugs and their generic equivalents differ by 
only a few percentage points on accepted measures of bioavailability (area under the plasma 
concentration curve or AUC) and peak exposure (maximum plasma concentration or 
Cmax).[8] 
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Regulation of generic immunosuppressants is stricter still. As a precautionary measure, the 
EMA has narrowed the acceptable difference in AUC between generic and proprietary 
versions. Marketing authorisation is granted only when the AUC ratio of test and reference 
product falls within a 90% confidence interval of 90% to 111%, narrower than the 80% to 
125% interval accepted for other drugs. 8] The summary of product characteristics also 
recommends that patients prescribed generic immunosuppressive drugs have their plasma 
concentrations monitored during the switch to minimise the risk of rejection.[9] This 
recommendation echoes normal clinical practice, as patients are monitored in a similar way 
during initial treatment with an immunosuppressant after a solid organ graft. 
In view of the continuing debate about the safety and effectiveness of generic 
immunosuppressive drugs, Molnar and colleagues undertook a systematic review and meta-
analysis of all studies published since 1980 that compared generic with innovator (originator) 
immunosuppressive drugs for people with a solid organ transplant.[4] 
They found that acute rejection was rare overall and that risk did not differ between groups 
of participants treated with a generic or an innovator drug.[4] The standard of methods of the 
published studies, however, was variable, with most studies having inadequate length of 
follow-up. Treatment failure can take time to emerge and can be missed by short term 
studies.[10] 
Their analysis of pooled pharmacokinetic data showed that generic immunosuppressants 
are bioequivalent according to conventional regulatory criteria (90% confidence interval for 
the AUC ratio no wider than 80% to 125%), but WKH\GRQ¶WDOZD\VPHHWWKHVWULFWHU(0$
criteria (90% confidence interval no wider than 90% to 111%). The small number of patients 
in some studies probably contributed to this finding as lack of power leads to wide 
confidence intervals. Sample sizes would have to increase up to eightfold in some studies to 
achieve the tighter confidence intervals required by the EMA.[11]  
For instance, the two trials of ciclosporin in recipients of kidney grafts had a mean number of 
30 patients. In a pooled analysis, the AUC UDWLRIDLOHGWRPHHWWKH(0$¶VFULWHULDIRU
bioequivalence. In a substantially larger pooled analysis of seven non-randomised studies 
PHDQVDPSOHVL]HWKH(0$¶VFULWHULDZHUHPHW 
 
In most reported trials, the point estimates for AUC and Cmax ratios were well within the 
expected range of being just a few percentage points higher or lower than 100%.[4] The 
problem might lie not with any clinically important difference between generics and 
originator immunosuppressants  but with the poor quality of the available evidence and 
ensuing difficulties with interpretation. We should also remember that WKH(0$¶VQDUURZLQJ
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of the bioequivalence limits was designed to further protect patients who were unlikely to be 
monitored correctly after switching to a generic immunosuppressant.[12] Studies in patients 
who are correctly monitored, as instructed by the summary of product characteristics, could 
provide additional evidence that immunosuppressive generics, used in the correct manner and 
with precautionary monitoring in place, can indeed be bioequivalent to originator drugs and 
achieve similar long term outcomes. 
Unfortunately, because of a relatively small number of eligible studies with hard to 
compare methods, and partly hampered by variable outcome reporting of crucial parameters, 
the study by Molnar and colleagues cannot establish with confidence whether or not generic 
immunosuppressive drugs are truly bioequivalent, effective, and safe.[4] We do know that 
generic immunosuppressive drugs, such as ciclosporin, have been on the market in Europe 
for more than 10 years and that pharmacovigilance systems have not identified any serious 
safety signals among the hundreds of thousands of doses prescribed and dispensed. While this 
observation is reassuring for clinicians and patients considering or undertaking a switch, 
bigger and better studies with longer follow-up are still required to fully examine any 
remaining concerns. In the meantime, clinicians could benefit from more education on the 
importance of monitoring plasma concentrations in patients who switch to a generic 
immunosuppressant. Monitoring is recommended by regulators, reassuring for patients, and 
might even improve adherence to treatment.[13] 
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